Adult mesenchymal stem cell therapy for myelin repair in Multiple Sclerosis
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Multiple sclerosis (MS) is a demyelinating immune-mediated disease of the central nervous system (CNS). It is the most frequent neurological disease in young adults and affects over 2 million people worldwide. Current treatments reduce the relapse rate and the formation of inflammatory lesions in the CNS, but with only temporary and limited success. Despite the presence of endogenous oligodendroglial progenitors (OPCs) and of spontaneous remyelination, at least in early MS its levels and its qualities are apparently insufficient for a sustained endogenous functional repair. Therefore, novel MS therapies should consider not only immunemodulatory but also myelin repair activities. Mesenchymal stem cells (MSCs) represent an attractive alternative to develop a cell-based therapy for MS. MSCs display stromal features and exert bystander immunemodulatory and neuroprotective activities. Importantly, MSCs induce oligodendrocyte fate decision and differentiation/maturation of adult neural progenitors, suggesting the existence of MSC-derived remyelination activity. Moreover, transplanted MSCs promote functional recovery and myelin repair in different MS animal models. Here, we summarize the current knowledge on endogenous mechanisms for remyelination and proposed autologous MSC therapy as a promising strategy for MS treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Németh, K., Leelahavanichkul, A., Yuen, P. S. T., Mayer, B., Parmelee, A., Doi, K., Robey, P. G., Leelahavanichkul, K., Koller, B. H., Brown, J. M., et al. (2009) · Nature Medicine · doi:10.1038/nm.1905 · Cited by 2,364 · cited 1×
“Additionally, MSCs inhibit the diff erentiation of monocytes into immature antigen-presenting myeloid DCs and modulate macrophage activity (Nemeth et al., 2009).”
Remyelination in the CNS: from biology to therapy
Franklin, R. J. M., & ffrench-Constant, C. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2480 · Cited by 1,544 · cited 1×
“Today, it is evident that myelin sheaths are re-established along demyelinated axons, restoring structure and function (Franklin and Ffrench-Constant, 2008; Lassmann et al., 1997; Smith et al., 1979; Woodruff and Franklin, 1999).”
Chain Migration of Neuronal Precursors
Lois, C., García-Verdugo, J.-M., & Alvarez-Buylla, A. (1996) · Science · doi:10.1126/science.271.5251.978 · Cited by 1,331
The Immunopathology of Multiple Sclerosis: An Overview
Lassmann, H., Brück, W., & Lucchinetti, C. F. (2007) · Brain Pathology · doi:10.1111/j.1750-3639.2007.00064.x · Cited by 1,182
Premyelinating Oligodendrocytes in Chronic Lesions of Multiple Sclerosis
Chang, A., Tourtellotte, W. W., Rudick, R., & Trapp, B. D. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa010994 · Cited by 991 · cited 1×
“…OPCs (Niehaus et al., 2000), the majority of data supports a failure of OPC differentiation and maturation in MS. OPCs are typically found in demyelinated areas, but they fail to diff erentiate and to remyelinate (Chang et al., 2002; Kuhlmann et al., 2008; Reynolds et al., 2002; Wolswijk, 1998).”
Matsushima, G. K., & Morell, P. (2001) · Brain Pathology · doi:10.1111/j.1750-3639.2001.tb00385.x · Cited by 984 · cited 2×
“Remyelination is quite evident one to two weeks after cuprizone removal and largely complete after four weeks (Matsushima and Morell, 2001; Silvestroff et al.).”
Origin of oligodendrocytes in the subventricular zone of the adult brain
Menn, B., Garcia-Verdugo, J. M., Yaschine, C., Gonzalez-Perez, O., Rowitch, D., & Alvarez-Buylla, A. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.1299-06.2006 · Cited by 972 · cited 3×
“These cells migrate towards the corpus callosum (CC), the striatum and to the fi mbria fornix, where they differentiate into oligodendrocytes (Menn et al., 2006).”
OBSERVATIONS ON ATTEMPTS TO PRODUCE ACUTE DISSEMINATED ENCEPHALOMYELITIS IN MONKEYS
Rivers, T. M., Sprunt, D. H., & Berry, G. P. (1933) · Journal of Experimental Medicine · doi:10.1084/jem.58.1.39 · Cited by 643
Sim, F. J., Zhao, C., Penderis, J., & Franklin, R. J. M. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-07-02451.2002 · Cited by 625
Wolswijk, G. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-02-00601.1998 · Cited by 562
Cited by
Applying extracellular vesicles based therapeutics in clinical trials – an ISEV position paper
Lener, T., Gimona, M., Aigner, L., Börger, V., Buzas, E., Camussi, G., Chaput, N., Chatterjee, D., Court, F. A., del Portillo, H. A., et al. (2015) · Journal of Extracellular Vesicles · doi:10.3402/jev.v4.30087 · Cited by 1,491
Self-citationSaeedi, P., Halabian, R., & Imani Fooladi, A. A. (2019) · Stem Cell Investigation · doi:10.21037/sci.2019.08.11 · Cited by 251
Abbasi-Kangevari, M., Ghamari, S.-H., Safaeinejad, F., Bahrami, S., & Niknejad, H. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00238 · Cited by 79
“However, remyelination is typically incomplete or defective and many lesions remain demyelinated (48, 49).”
BackgroundQin, D., Wang, C., Li, D., & Guo, S. (2024) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.105487 · Cited by 27
Distinct transcriptional changes distinguish efficient and poor remyelination in multiple sclerosis
Chen, J. Q. A., McNamara, N. B., Engelenburg, H. J., Jongejan, A., Wever, D. D., Hopman, K., van Rixel, E., Nijhuis, P. J. H., de Winter, F., Moerland, P. D., et al. (2025) · Brain · doi:10.1093/brain/awae414 · Cited by 17
Metadata
- Authors
- Rivera, F. J., & Aigner, L.
- Venue
- Biological Research
- Published
- 2012
- Volume
- 45
- Issue
- 3
- Pages
- 257-268
- ISSN
- 0716-9760 (ISSN-L)
- OpenAlex
- W2117858034
- Cited by
- 53
- References
- 30
- FWCI
- 2.70
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Adult mesenchymal stem cell therapy for myelin repair in Multiple Sclerosis. https://app.cochat.ai/papers/10.4067/s0716-97602012000300007
- The paper
- Rivera, F. J., & Aigner, L. (2012). Adult mesenchymal stem cell therapy for myelin repair in Multiple Sclerosis. Biological Research. https://doi.org/10.4067/s0716-97602012000300007
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.